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Takotsubo syndrome (TTS) is a recently identified cardiac disease, which is far from being completely known. ,e aims of this
narrative review are to provide a better understanding of the pathophysiological features of TTS and to update clinical findings in
order to improve the management of subjects affected by this syndrome (according to the most recent consensus papers issued by
the international scientific societies). We based our search on the material obtained via PubMed up to April 2019. ,e terms used
were “Takotsubo Syndrome and Takotsubo cardiomyopathy” in combination with “heart failure, pathophysiology, complications,
diagnosis, and treatment.” TTS is a reversible form of ventricular dysfunction usually characterized by akinesia of the apex in the
absence of obstructive coronary artery disease. In its initial phase, TTSmay be indistinguishable fromAMI and is usually triggered
by a sudden emotional/physical stressor which abruptly increases catecholamine levels. However, the mechanisms by which
catecholamines or other unidentified molecules can cause myocardial dysfunction is unknown. In-hospital stay may be hampered
by various life-threatening complications, while data on long-term survival remain scarce and unclear. Furthermore, TTS may
sometimes recur. We believe that TTS is clearly a much more complex condition than previously thought. Much remains to be
discovered about its pathophysiologic mechanisms, the role of the link between the heart and brain and that of triggering factors
and gender, and the reasons why this syndrome displays different phenotypes and sometimes recurs. Undoubtedly, preliminary
evidence from pathophysiological studies (mainly genetic studies) has shown promising advances. However, prospective ran-
domized clinical trials are still needed in order to identify and to tailor the best medical treatments for TTS patients.
1. Introduction
In the following paragraphs, we will attempt to update
knowledge on both the pathophysiological and clinical aspects
of takotsubo syndrome (TTS). We based our search on the
material obtained via PubMed up to September 2019. ,e
terms used were “Takotsubo Syndrome and Takotsubo car-
diomyopathy” in combination with “heart failure, patho-
physiology, complications, diagnosis, and treatment.”
1.1. History of the Disease. Several terms (such as happy
heart syndrome, broken heart syndrome, and takotsubo
cardiomyopathy) have been used to refer to the recently
defined takotsubo syndrome (TTS).,e first case of TTS was
described in Japan (Hiroshima City Hospital) in 1983 [1].
Subsequently, other cases were diagnosed in Japanese pa-
tients, leading to the hypothesis that this cardiac disease was
typical of Asian populations. More recently, however, a
French research group published a case series of TTS in a
Caucasian population [2]. TTS gained international atten-
tion in the early 2000s [3], when the first diagnostic criteria,
including apical dyskinesis/akinesis, absence of obstructive
coronary artery disease (CAD) on coronary angiography,
new electrocardiographic abnormalities, modest elevation in
serum cardiac troponin in the absence of
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pheochromocytoma, and myocarditis, were published [4].
After the definition of TTS, the first cohorts enrolling
around hundred patients allowed description of the heart as
indistinguishable from the stunned myocardium [5]. Sub-
sequently, TTS registries were instituted in several countries.
In the EU, Spain, Germany, France, and Italy created na-
tional registries [6–9]. In Japan, several cohorts and regis-
tries were created [10, 11], suggesting the need to collaborate
in the creation of an international registry, such as the
International Takotsubo (InterTAK) Registry, which was
designed as an international, multicenter, prospective and
retrospective, and observational study of patients with TTS
[12]. Currently, more than 35 international cardiovascular
centers in 15 countries contribute to this single registry,
including centers in Argentina, Australia, Austria, the Czech
Republic, Denmark, Finland, France, Germany, Italy, New
Zealand, Poland, Portugal, Switzerland, the United King-
dom, and the United States. ,e data collected by this
registry have enabled new diagnostic criteria and a di-
agnostic algorithm to be drawn up. ,e exclusion of a
clinically relevant coronary stenosis is to be considered an
essential element of this diagnostic algorithm. Moreover,
according to the most recent diagnostic criteria, the di-
agnosis of TTS must also be based on the absence of culprit
coronary disease [13, 14] although it is known that TTS may
be associated with mild forms of coronary atherosclerosis
[15]. TTS is gradually being better investigated and un-
derstood, and the number of diagnoses is increasing, the
disease being included in the recent 4th universal definition
of myocardial infarction by the European Society of Car-
diology (ESC) [16]. In Western countries, a female preva-
lence has been observed, with a female-to-male ratio of 9 :1
[17]. However, in Japan, men are more affected than women,
for unknown reasons [18]. Furthermore, women are more at
risk of developing TTS during the menopausal period,
suggesting a possible hormonal involvement [19–22].
However, further data are needed in order to confirm this
association.
1.2. Pathophysiology. Several pathophysiological mechanisms
underlying TTS pathophysiology have been hypothesized. ,e
description of takotsubo as a syndrome due to “broken heart”
first suggested a critical activity of catecholamines. Indeed,
increased circulating levels of these hormones were observed
byWittesten and coworkers in a pilot study comparing patients
with takotsubo syndrome with those with acute myocardial
infarction (AMI) in Killip class III [3]. ,e high level of cat-
echolamine seems to be due to hyperactivation of the hypo-
thalamo-pituitary gland-adrenal system in response to an
exogenous trigger, which is not always easily recognized.,ese
findings suggested a potential heart-brain interaction in the
pathophysiology of TTS. In this regard, the limbic network,
comprising the insula, amygdala, cingulate cortex, and hip-
pocampus, and the autonomic nervous system appear to suffer
some degree of dysfunction in patients with TTS in com-
parison with healthy controls [23]. Moreover, TTS recurs in
patients with ictus or aneurysmal subarachnoid hemorrhage or
epilepsy, which affect the abovementioned nervous regions
[24–27]. It has been discussed whether the transient, regional
left ventricular dysfunction associated with several neurological
disorders shares the same pathophysiology with TTS without a
clear neurological disease and whether it is appropriate to
include these patients in a single category of stress cardio-
myopathy. ,is issue requires additional evidence from both
clinical and basic research studies.
,e supposed mechanisms by which catecholamine ex-
cess can aggravate myocardial stunning remain to be clarified.
,e spasm of epicardial arteries and the acute worsening of
endothelial dysfunction have been investigated without def-
inite conclusions being reached [28]. Another hypothesis
focused on microcirculation dysfunction, which may be
inferred from the presence of reduced TIMI flow, and also on
endothelial cell necrosis in myocardial biopsies [29, 30]. In
addition, intravenous administration of adenosine has been
shown to transiently improve myocardial perfusion, wall
motion score index, and left ventricular ejection fraction
(LVEF) in TTS, suggesting that intense microvascular con-
striction could play a major pathophysiological role [31].
Transient LV dysfunction in TTS could also result from
detrimental catecholamine-induced activity on cardiomyocytes.
It has been hypothesized that a high level of epinephrine sig-
naling takes place through the pleiotropic 2-adrenergic receptor
(2AR) from canonical stimulatory G-protein-activated car-
diostimulant to inhibitoryG-protein-activated cardiodepressant
pathways. Because the majority of B2 receptors are located on
the LV apex, altered intracellular signaling may be the cause of
the apical ballooning appearance [32].
Finally, it has been suggested that some anatomic
variants of coronary vessels may also play a role [33].
Indeed, Arcari and coworkers [34] demonstrated that
coronary artery tortuosity and a long, recurrent wrap-
around the left anterior descending artery might act as a
potential pathogenic substrate in TTS. It has been hy-
pothesized that, in the presence of sympathetic overdrive,
the subsequent tachycardia, with decreased diastolic time
and increased contractility, could aggravate the hemody-
namic effect of these anatomic variants (also including
myocardial bridges), thus facilitating the onset of the pe-
culiar wall motion abnormalities of TTS. Taking into ac-
count both the presence of familial cases and the fact that
only a small percentage of women who undergo psycho-
logical stress develop TTS, the existence of a genetic pre-
disposition may be hypothesized [35]. However, genetic
studies have yielded conflicting results concerning the
potential association between TTS and polymorphisms of
adrenergic receptors [36, 37]. In the largest genetic study,
Eitel et al. [36] detected 68 promising candidate loci;
unfortunately, none of these reached genome-wide sig-
nificance. Nevertheless, this result may be considered an
important step towards further insights into a potential
genetic predisposition for the development of TTS.
Some genetic variants probably interact with the envi-
ronment, and certain predisposed individuals may develop
TTS more easily. In accordance with all these data, since
many factors have been called into play in the pathophys-
iology of TTS, the ultimate etiology of the disease must be
regarded as multifactorial.
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1.3. Clinical, Laboratory, and Imaging Presentation. Like an
AMI, TTS can present with acute chest pain, dyspnea, and
syncope [38]. On the contrary, patients may sometimes be
completely asymptomatic, and TTS is discovered because of
ECG changes or imaging alterations [39]. Moreover, a
minority of TTS patients may suffer symptoms due to
complications such as heart failure, pulmonary edema,
stroke, cardiogenic shock, or cardiac arrest [38].
Historically, TTS has been related to a preceding
emotional stressor. However, international takotsubo reg-
istries have revealed that, in 30% of patients, no trigger event
can be identified, and that both emotional trauma and
physical stressors can precede TTS [38, 40, 41]. In addition,
in men, physical traumas seem to be more frequent than
emotional triggers, whereas, in women, emotional stressors
are more frequently detected [4, 9]. As TTSmay recur, it is of
paramount importance to identify specific triggers. In an
interesting paper, Finsterer and coworkers discussed the
matter of what triggers TTS in cases without obvious triggers
and underlined the concept that triggers have to be both
identified and defused [42]. In order to detect the stressor
stimulus triggering TTS, it is mandatory to scrutinize the
individual’s history for such events. However, patients may
be sometimes reluctant to talk about stressful events; if so,
relatives or close friends can be also consulted [42]. Finally,
the presence of a preexisting subclinical cardiomyopathy
may be a copathophysiological factor; any such condition
must be identified and monitored, as it can worsen the
outcome. Morner and colleagues described the case of heart
failure with echocardiographic findings of a large aneurism
of the left ventricle, which occurred after gastrointestinal
surgery in a patient with hypertrophic obstructive cardio-
myopathy [43]. ,e authors suggested that a superimposed
TTS may account for the occurrence of heart failure
symptoms and signs in a portion of cases with preexisting
myocardial disease. Unfortunately, in this case, the lack of
serial echocardiograms did not allow this to be ascertained.
Other authors have described cases of TTS occurring in the
context of either hypo- or hyperthyroidism, which may be
associated with coronary microcirculatory dysfunction and
abnormal myocardial expression of adrenergic receptors or
with hyperactivation of the adrenergic system, which might
serve as a substrate for the myocardial stunning [44, 45].
With regard to EKG alterations, TTS often presents ab-
normalities, the most common being ST-segment elevation,
which is found in 44% of cases and mimics an acute
myocardial infarction. In addition, T-wave inversion may
sometimes also occur [38]. Despite some overlap between
anterior STEMI and TTS, some EKG criteria have been
proposed in order to distinguish between these two diseases
[46, 47]. In TTS, ST-segment elevation is mainly localized in
V2–V5 leads and in II and aVR. By contrast, in anterior
STEMI, ST-segment elevation is detectable on precordial
leads V1–V4 and limb leads I and aVL. Another criterion is
the absence of reciprocal changes in inferior leads in TTS
[46]. Furthermore, ST-segment elevation occurs more fre-
quently in aVR and less frequently in V1, which is generally
involved in anterior STEMI. ST-segment elevation that is
limited to the inferior leads (II, III, and aVF) is distinctly
uncommon in TTS [46–48].
Another EKG feature of TTS is the absence of Q waves.
Furthermore, ST-segment depression is uncommon in TTS,
occurring in less than 10% of patients, while it occurs in more
than 30% of other acute coronary syndrome (ACS) patients
[38]. In addition, similarly to ACS, in TTS, the EKG displays a
temporal evolution, typically with a resolution of initial ST-
segment elevation (if present), followed by progressive
T-wave inversion and QT interval prolongation, which may
be considered another characteristic of TTS [49, 50].
,e reversible nature of TTS has given rise to the belief
that it is a benign disease. However, the registries that have
been created in recent years have revealed that TTS has a
similar rate of in-hospital complications to AMI [38, 39].
TTS patients need to be monitored, owing to the various in-
hospital complications that may arise as a result of electrical
and hemodynamic instability, such as cardiac arrhythmias,
cardiogenic shock, ventricular thrombus, pulmonary edema,
ventricular septal defect, and free-wall rupture. Further-
more, male patients have up to threefold higher rate of death
and major adverse cardiac and cerebrovascular events,
contributing to a higher mortality rate [39].
In-hospital complications may include various forms of
arrhythmia. Patients with TTS often have sinus tachycardia
although sinus bradycardia or other bradyarrhythmias may
also occur. Moreover, multiple atrial and ventricular pre-
mature beats, sinus node dysfunction (SND), asystole,
paroxysmal supraventricular tachycardia (PSVT), atrial fi-
brillation (AF), nonsustained and sustained ventricular
tachycardia (VT) (both monomorphic and polymorphic
torsades de pointes (TdP)), ventricular fibrillation (VF),
ventricular asystole, pulse-less electrical activity, sudden
cardiac death (SCD), and right and left bundle branch blocks
can be detected [51].
Atrial fibrillation (AF) is present in approximately 4.7%
of patients with TTS, and permanent oral anticoagulation
should be considered [39]. Cardiac magnetic resonance
imaging has revealed an association between transient
myocardial edema, as evidenced by T2-weighted sequences
and dynamic T-wave inversion and QT prolongation
[52–54]. Finally, arterial thromboembolism constitutes the
second most frequent complication of TTS [55–57]. In a
recent study, Abanador-Kamper and coworkers found that
stroke in TTS had an event rate of 2.8% after 30 days and
4.2% after 12months [57]. Francesco Santoro and col-
leagues identified some characteristics linked to throm-
boembolism and created a therapeutic algorithm to
potentially improve the clinical management [58]. For
instance, in the case of an apical ballooning pattern and
increased admission levels of troponin-I (>10 ng/mL), oral
anticoagulation must be considered, while in the case of
midventricular/basal ballooning or apical ballooning as-
sociated with troponin-I levels <10 ng/mL, oral anti-
coagulation should not be initiated. A simple combination
of echocardiographic parameters (apical ballooning pat-
tern), EKG data (ST-elevation on admission and persisting
after 72 h), and laboratory values (troponin serum levels)
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could be useful to the appropriate therapeutic management
of oral anticoagulation in TTS [59].
On echocardiography, circumferential abnormalities of
anterior, inferior, and lateral ventricular wall contraction
extending beyond a single epicardial vascular territory can
be considered a hallmark of TTS [59]. Also, a hyperkinetic
basal segment is currently described in the most common
form of TTS. Other contraction patterns may be present
during the acute phase of TTS, such as midventricular
akinesia [60], basal segment akinesia with midventricular
and apical sparing [61], and the focal variant, characterized
by focal wall motion abnormalities [62].
Furthermore, echocardiographic parameters may be
useful predictors of adverse outcomes. Indeed, adverse
outcomes can be predicted by low left ventricular ejection
fraction, increased LV filling pressure, and moderate-to-
severe mitral regurgitation at 4–6 weeks [63]. Wall motion
abnormalities tend to revert in 4–8 weeks. Another im-
portant diagnostic tool is cardiac magnetic resonance
(CMR), which is usually performed in a subacute phase
[64]. As this technique has higher resolution, it can better
identify wall motion alterations and complications; it also
offers a unique combination of safety, detailed anatomical
visualization, and tissue characterization data [65]. ,e
most recent diagnostic criteria of TTS highlight the es-
sential role of CMR, not only for morphological charac-
terization but also for the exclusion of other entities that
otherwise would not be ruled out, particularly myocarditis
and myocardial infarction with nonobstructive coronary
arteries (MINOCA). In an article published in JAMA in
2011, CMR diagnostic criteria for TTS were established
[66]: firstly, the presence of wall motion alterations is
necessary; secondly, the dysfunctional segments must show
edema on T2W sequences, and finally, late gadolinium
enhancement (LGE) should not be present. ,e absence of
LGE suggests that there is no fibrosis or increased extra-
cellular space. However, in 9% of cases, some spots of fi-
brosis have been found, and these are related with the worst
prognosis [67].
CMR can be useful in distinguishing the focal forms of
TTS from an ACS or myocarditis, in which wall motion
alterations do not extend beyond the distribution of a single
coronary territory; however, even this tool may sometimes
fail to obtain a differential diagnosis. Undoubtedly, coronary
angiography and ventriculography are essential to the dif-
ferential diagnosis from ACS [68]. Nuclear medicine tech-
niques may be usefully used for the diagnosis of TTS and
have increased our knowledge of the pathophysiological
mechanisms. Indeed, they have demonstrated that dys-
functioning segments present a pattern of severe de-
nervation and metabolic glucose uptake, which ameliorates
and even normalizes, during follow-up as a result of the
improvement in myocardial function. Studies based on
positron emission tomography and myocardial SPECT have
shown a discrepancy between normal perfusion and reduced
glucose utilization in TTS, commonly known as “inverse
flow metabolism mismatch” [69, 70].
In the acute phase, TTSmay be clinically indistinguishable
from acute MI but, by means of positron emission
tomography, it has been successfully distinguished from acute
coronary artery disease, thereby also offering a new patho-
physiological explanation for this particular syndrome. Apical
ballooning syndrome may be considered a disorder at the
cellular level rather than a structural contractile disease of the
myocardium, as a transient decrease of glucose metabolism
might be related to a coronary microcirculation impairment,
followed by prolonged myocardial stunning [71].
Serum troponin is usually positive in the acute phase
of TTS, but its values tend to be low in comparison with
the extension of myocardial dysfunction. It is commonly
believed that troponin levels in AMI are higher than in
TTS, though the InterTAK Registry has shown no dif-
ference between the two pathologies [63]. On the con-
trary, the hs-TnT/CKMB ratio could be helpful in
differential diagnoses, in that it has been found to be
significantly higher in TTS patients than in NSTEMI and
STEMI [72].
During the course of TTS, serum levels of NT-proBNP
also increase. Nef and colleagues found that serum levels of
NT-proBNP on admission were correlated to the severity of
post-TTS complications during hospitalization [73]. ,e
higher serum levels of NT-proBNP were on admission, and
more clinical complications were present, i.e., pulmonary
edema and malignant ventricular arrhythmia. Furthermore,
Frochlich and coworkers [74] have suggested that TTS
presents with specific NT-proBNP/myoglobin and NT-
proBNP/troponin T ratios that can be differentiated from
those observed in NSTEMI and STEMI.
1.4. Diagnostic Criteria. In recent years, there have been
several attempts to create effective diagnostic criteria for
TTS. ,e most widely used since 2018 have been the Mayo
Clinic Diagnostic Criteria [4, 75]. ,e European Society of
Cardiology (ESC) has also established the International
Takotsubo Diagnostic Criteria (InterTAK Diagnostic
Criteria) [13], which implement a diagnostic algorithm and
assign a score to TTS. ,e InterTAK Diagnostic Score
considers the following variables and gives each one a
specific score [13, 14]: female sex; emotional stress and
physical stress; no ST depression; psychiatric disorders;
neurologic disorders; and QTc prolongation. If the score is
≤70 points, the probability of having TTS is intermediate or
low, whereas a score ≥70 indicates a high probability
(Table 1). ,e patients with a low probability of TTS and a
suspicion of ACS should undergo coronary angiography
and left ventriculography, while in patients with a high
score, transthoracic echocardiography (TTE) should be
performed. Wall motion abnormalities on TTE help to
decide the next step; if the typical presentation with cir-
cumferential ballooning pattern is absent, coronary angi-
ography with left ventriculography is the choice. In normal
coronaries and typical ballooning, myocarditis must be
excluded. ,e algorithm includes some clinical markers of
myocarditis called red flags (signs and symptoms of viral
infection, elevated ESR and/or PCR, and pericardial effu-
sion); if these are present, CMR is the only tool that
can help.
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2. Treatment
,emanagement of TTS is based on both clinical experience
and Expert Consensus, as no prospective randomized
clinical trials have been carried out. Table 2 summarizes the
main drugs that are recommended to treat TTS.
2.1. Pharmacological Treatments. Owing to the similarities
in clinical presentation of AMI and TTS in the earliest phase,
the therapy is the same: antithrombotic, heart failure drugs,
and aggressive statin therapy should be undertaken [39,
76–78]. Once the diagnosis has been established, if con-
comitant atherosclerosis is present, statin and aspirin are
recommended. As high levels of circulating catecholamines
have been detected in TTS, it is not recommended that
epinephrine and norepinephrine be used as inotropic sup-
port; rather, levosimendan, which is a Ca2+ sensitizer, could
fulfill this function [79]. Its use, however, is limited to those
patients with impaired systolic function, without left ven-
tricular outflow tract obstruction and with systolic blood
pressure >90mmHg. Levosimendan should be infused for
24 h at a dose of 0.1 μg/kg/min, without loading dose. During
infusion, the patient should be hemodynamically and EKG
monitored for the risk of hypotension and arrhythmias [79].
,e effects of catecholaminergic storm during TTS could be
attenuated by the use of beta-blockers. In an animal trial,
both alpha- and beta-blockers were used with positive re-
sults, but more data are required before these strategies can
be used in humans [80]. Furthermore, beta-blockers can be
used safely in 20% of TTS patients with left ventricular
outflow tract obstruction (LVOTO), as they seem able to
reduce the intra-aortic gradient [81].
In addition, other studies have found an increasing
concentration of beta-2 receptors from the base to the apex
of the LV and a higher concentration of beta-1 in the basal
left ventricular segments, suggesting the use of selective beta-
1 beta-blockers [82]. Owing to the fact that TTS patients
sometimes present psychiatric or neurologic pathologies and
so have prolonged QTc (>500msec) and increased risk of
TDP [83], we must pay particular attention when pre-
scribing beta-blockers for these subjects [83]. For this rea-
son, they should be monitored hemodynamically and by
means of EKG, and short-acting BB should be preferred [84].
Regarding the long-term use of BBs, even though they can
counterbalance the action of catecholamines, no studies
have demonstrated a reduction in recurrences [85, 86].
Randomized controlled trials need to be conducted in order
to clarify the real efficacy of BBs.,is category of drug seems
capable of promoting the recovery of the LV, reducing not
only mortality at 1 year but also the number of recurrences
[38]. By contrast, BBs have not shown these potentialities
[85] even though the combination of BBs and ACI/ARBS
appears to be connected with lower rates of recurrences
[86, 87]. Diuretics can be used to reduce edema, while ni-
trates are useful to ameliorate LV and RV filling pressures
and after-load; however, nitrates should be avoided in the
case of LVOTO [78].
2.2. Mechanical Cardiac Support (MCS). If patients present
with cardiogenic shock, the use of mechanical circulatory
support as a bridge to recovery therapy can be considered.
,e IABP has not yielded positive results, as it can raise
the transaortic gradient [88, 89]. ,e TandemHeart is
theoretically useful, but its efficacy has not been docu-
mented in the current literature [90]. ,e ECMO reduces
preload and increases end-organ perfusion at the cost of
increased after-load, causing a possible rise in the
transaortic gradient and worsening of mitral regurgitation
[91]. Impella appears to provide the most effective sup-
port, as it has been seen to overcome LVOTO and reduce
mitral regurgitation [92, 93].
2.3. Prognosis and Survival. Available data on long-term
survival after TTS are limited. In 2007, Elesber and co-
workers [94] reported that long-termmortality did not differ
between patients with TTS and an age-matched population.
Conversely, Sharkey et al. [95] found that all-cause mortality
during follow-up exceeded that of a matched general pop-
ulation, with most deaths occurring in the first year. More
recently, it has been reported that long-term mortality in
patients with TTS is similar to that of patients with CAD.
Specifically, TTS patient data from the Swedish Angiography
and Angioplasty Registry (SCAAR) from 2009 to 2013 were
compared with data from patients with and without CAD
and demonstrated that mortality rates for TTS were worse
than in patients without CAD and comparable to those of
patients with CAD [96]. In the largest TTS registry to date,
death rates are estimated to be 5.6% and the rate of MACCE
9.9% per patient-year, suggesting that TTS is not a benign
disease [38]. A study conducted by Ghadri et al. found that
patients with the typical TTS type have a comparable out-
come to patients presenting with the atypical type, even after
adjustment for confounders, suggesting that both patient
groups should be equally monitored in the long term [62].
On the contrary, 1-year mortality differs between the two
groups, as it is driven by clinical factors, including atrial
fibrillation, LVEF <45% on admission, and neurological
disorders, rather than by the TTS type [62]. In a smaller
study, predictive factors of long-term mortality in TTS were
male sex, Killip class III/IV, and diabetes mellitus [97]. ,e
prognostic role of diabetes mellitus is controversial, as it is
postulated that it may exert a protective effect in TTS, given
that the prevalence of diabetes mellitus in TTS is lower than
Table 1: Diagnostic criteria used to distinguish takotsubo syn-
drome (TTS) from acute coronary syndrome (ACS).
InterTak diagnostic score
Female sex 25 points
Emotional stress 24 points
Physical stress 13 points
No ST depression 12 points
Psychiatric disorders 11 points
Neurologic disorders 9 points
QTc prolongation 6 points
Score >70 points: high probability of TTS
Score ≤70 points: low/intermediate probability of TTS
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expected for an age- and sex-matched population [98]. Some
studies, though limited by their population size and ex-
perimental design, have suggested that patients with diabetes
mellitus have a more favorable in-hospital and 1-year
outcome [99, 100]. Recent reports have suggested a high rate
of noncardiovascular long-term mortality in TTS, which
could be ascribed to malignancies [100, 101]. Another
possible complication is that of recurrences. Recurrence may
take place after as little as 3 weeks, or as late as several years,
after the initial event [39]. Furthermore, in recurrent TTS,
the LV ballooning pattern may differ; for example, apical
ballooning may occur during the initial event and mid-
ventricular ballooning during the second event [102]. ,e
recurrence rate of TTS has been reported to be up to 12%
over a mean follow-up of four years and may display a
variable pattern [102]. Finally, we should remember that the
prognosis of TTS may differ according to the type of trigger.
When TTS is induced by a physical event, rather than by
emotional stress, the prognosis is worse. Indeed, in the
presence of physical stressors, a fourfold higher mortality
risk has been found, while in the presence of unidentifiable
triggers, the risk is doubled [103].
3. Conclusions and Perspectives
TTSmust be considered an intriguing and fascinating disease,
owing to the fact that it is a far more diverse condition than
previously thought and that the pathophysiologic mecha-
nisms are not completely understood. Indeed, although the
correlation of TTS with a surge in catecholamines has been
clearly demonstrated, there is no established pathophysio-
logical mechanism; however, several promising hypotheses
have been put forward. Undoubtedly, a link between the brain
and heart seems to play a key role. ,e predominance of
postmenopausal women in TTS suggests that sex hormones
and the endocrine system may play a role. However, much
remains to be discovered about TTS and its pathophysiology.
Furthermore, many issues remain to be investigated, such as
the role of triggering factors and gender, why TTS displays
different phenotypes, and which patients are most prone to
developing TTS or its recurrences. To answer these questions,
additional studies are needed. While TTS was formerly
considered a benign disease, recent studies have shown that it
presents in-hospital complications and mortality that are
comparable to those of ACS. However, data on long-term
survival are scarce and somewhat unclear. Randomized,
prospective, multicenter trials involving larger numbers of
patients must be conducted in order both to identify effective
evidence-based therapies, in the in-hospital phase and the
longer term, and to prevent recurrences.
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I. R. Jiménez, “Sı́ndrome de Takotsubo. Utilidad de los
estudios de medicina nuclear,” Revista Española de Medicina
Nuclear, vol. 30, no. 2, pp. 104–106, 2011.
[71] T. Yoshida, T. Hibino, N. Kako et al., “A pathophysiologic
study of tako-tsubo cardiomyopathy with F-18 fluo-
rodeoxyglucose positron emission tomography,” European
Heart Journal, vol. 28, no. 21, pp. 2598–2604, 2007.
[72] C. Pirlet, L. Pierard, V. Legrand, and O. Gach, “Ratio of high-
sensitivity troponin to creatine kinase-MB in takotsubo
syndrome,” International Journal of Cardiology, vol. 243,
pp. 300–305, 2017.
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